Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
Sofinnova Partners raises €725M crossover fund for late-stage European biotechs
00

Sofinnova Partners raises €725M crossover fund for late-stage European biotechs

Nov 16, 2026

Paris-based Sofinnova Partners announced on November 16, 2026, that it raised €725 million ($815 million) for its largest crossover fund to date, Sofinnova Crossover II. The fund addresses a European scale-up financing gap by supporting roughly 15 late-stage drugmakers and medtech firms, including early capital deployments to CellCentric and Hemab Therapeutics. Sofinnova manages approximately €4 billion in total assets.

Sofinnova Crossover II fundraising and size

  • ▪Sofinnova Crossover II is the largest crossover fund raised by Sofinnova Partners to date, bringing the firm's total assets under management to approximately €4 billion
  • ▪Paris-based venture capital firm Sofinnova Partners announced it raised €725 million for its second crossover fund, Sofinnova Crossover II

Sofinnova Crossover II strategy and investments

  • ▪Sofinnova Crossover II has already deployed capital into clinical-stage biotechnology companies CellCentric and Hemab Therapeutics
  • ▪Sofinnova Crossover II plans to invest in approximately 15 late-stage drugmakers and medical device developers nearing product commercialization, primarily in Europe

Executives on European life sciences capital

  • ▪Sofinnova Partners chairman Antoine Papiernik stated that the €725 million fund scale reflects European life sciences maturity and rising capital demand to reach global markets
  • ▪Sofinnova Partners partner Kinam Hong stated that Europe faces a scale-up financing problem rather than an innovation problem for life sciences companies

Past successful Sofinnova biotech investments

  • ▪Sofinnova Partners backed Verona Pharma, which brought a lung disease treatment to commercial market before being acquired by Merck & Co.
  • ▪Sofinnova Partners partner Kinam Hong led an initial investment in immune drugmaker Abivax, which later reached a public market valuation of approximately $7 billion

Early-stage biotech investments

  • ▪In 2025, Sofinnova Partners raised €650 million ($750 million) to support young therapeutics and medical technology developers
  • ▪In 2026, Sofinnova Partners posted investments in early-stage biotech startups including Alethio Therapeutics, Bionyra, and T-Therapeutics

Biotechnology venture funding activity in 2026

  • ▪According to an October 2026 report by investment firm William Blair, biotechnology venture capital firms raised over $13 billion in new funding during 2026
  • ▪BioPharma Dive tracking data shows top sector investors completed more than 70 private funding rounds for clinical-stage biotechs in Phase 1 trials or later during 2026

3 sources

BioPharma Dive
One of Europe’s leading VCs banks a €725M ‘crossover’ fund
View source article
Axios
Sofinnova Partners raises €725M fund to back late-stage biotechs
View source article
Endpoints
Sofinnova amasses €725M for late-stage European biotechs
View source article

Featured stories

View more in Biotech innovation

LangChain raises $300 million at $3 billion valuation

Nov 12, 2026 · 2 sources

Q-CTRL raises $290 million Series C at over $1 billion valuation for quantum software

Nov 12, 2026 · 3 sources

Norwest raises $4 billion fund focused on AI investments

Nov 12, 2026 · 2 sources

Fractile raises $720 million Series C at $7 billion valuation for AI chips

Nov 11, 2026 · 3 sources

Story comments

Loading comments…

Related entities

EuropeParis

Related Projects

BioPharma Dive

Topics

Biotech innovationBiotechnologyPharmaceutical IndustryVenture capital funding

Featured stories

View more in Biotech innovation

LangChain raises $300 million at $3 billion valuation

Nov 12, 2026 · 2 sources

Q-CTRL raises $290 million Series C at over $1 billion valuation for quantum software

Nov 12, 2026 · 3 sources

Norwest raises $4 billion fund focused on AI investments

Nov 12, 2026 · 2 sources

Fractile raises $720 million Series C at $7 billion valuation for AI chips

Nov 11, 2026 · 3 sources